[California Life Sciences' Spring Innovation Showcase]
- [NEWS] 青年日報 : NSTC Leads 8 Biomedical Startups to the 2025 North America BIO International Convention
- [NEWS] 中時新聞網 - 工商時報 : Emerging Stock Biotech Family Gains New Powerhouse; Pharmasaga Soars Over 100% on First Day of Listing
- [NEWS] 中時新聞網 : New Force in New Drug Stocks! Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
- [NEWS] 中時新聞網 - 工商時報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
- [NEWS] 工商時報 : Emerging Stock Biotech Family Gains New Powerhouse; Pharmasaga Soars Over 100% on First Day of Listing
- [NEWS] 工商時報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
- [NEWS] 自由時報-自由財金 : New Drug to Reverse Diabetes? Pharmasaga Expected to List on Emerging Stock Market on 27th at NT$120
- [NEWS] 自由時報 : New Drug to Reverse Diabetes? Pharmasaga Expected to List on Emerging Stock Market on 27th at NT$120
- [NEWS] 台灣新生報 : Pharmasaga to List on Emerging Stock Market Tomorrow at NT$120 Per Share
- [NEWS] TVBS新聞網 : Pharmasaga Develops Novel Diabetes Drug with 'Reversal Potential'; Listing on Emerging Stock Market on Nov. 27
- [NEWS] 壹蘋果新聞網 : Targeting the Multi-Billion-Dollar Diabetes Drug Market; Pharmasaga to List on Emerging Stock Market the Day After Tomorrow with New Drug Development
- [NEWS] 環球生技 : Pharmasaga's Innovative Drug for Type 1/2 Diabetes Plans Phase II, Creates Buzz Ahead of Emerging Stock Listing
- [NEWS] GENE ONLONE : Pharmasaga Pre-Listing Investor Conference: Diabetes New Drug Shows Reversal Effect in Animal Models
- [NEWS] 財訊快報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120; New Type 2 Diabetes Drug to Announce Phase Ib Clinical Data in H1 Next Year
- [NEWS] 發達網 : Pharmasaga to List on Emerging Stock Market on 27th; Type 2 Diabetes Phase Ib Clinical Trial Aims for Completion Next Year
- [NEWS]
自立晚報 : Pharmasaga Lists on Emerging Stock Market; Innovative Diabetes Reversal Therapy Targets Market
- [NEWS] anue鉅亨網 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
- [NEWS] anue鉅亨網 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
- [NEWS] 優分析 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
- [NEWS] 經濟日報 : Biotech Newcomer Pharmasaga Lists on Emerging Stock Market on 27th at NT$120; Developing Diabetes Reversal New Drug PS1 to Enter International Market
- [NEWS] 聚財網 : Biotech Newcomer Pharmasaga Lists on Emerging Stock Market on 27th at NT$120; Developing Diabetes Reversal New Drug PS1 to Enter International Market
[Pharmasaga participate in Bio+Health Track Dinner]
[Pharmasaga participate in SkyDeck x ITRI : Innovation, investment and Global Startup Growth]
[Pharmasaga participate in ITRI : Pitch and Investor Meetup]
[Pharmasaga participate in Berkeley SkyDeck Pitch Day]
A monumental milestone for Pharmasaga (7878.TW) as we advance into the global diabetes treatment market! We are thrilled to announce that we have officially received the prestigious TREE Program subsidy grant from the Department of Industrial Technology, MoEA.
By Reporter 吳典叡 / Comprehensive Report
The US BIO International Convention is a major global event on the global biotechnology and pharmaceutical sector calendar, bringing together top pharmaceutical companies, biotech startups, and investors from around the world. The convention offers extensive opportunities for business collaboration, particularly in licensing, technology transfer,...
Pharmasaga officially initiated its Phase I clinical trial in December 2023, following dual approval from the Taiwan Food and Drug Administration (TFDA) and the U.S. Food and Drug Administration (USFDA).